Tenon Medical, Inc. (NASDAQ: TNON) has witnessed a significant uptick in its stock value following the announcement of its new Catamaran SE Sacroiliac Joint Fusion System. As of the latest pre-market update, shares of TNON have surged by an impressive 235.68%, reaching a trading price of $14.77.
Tenon Introducing the Catamaran SE System
Tenon Medical (TNON) has revealed plans for the initial alpha launch of its Catamaran SE Sacroiliac Joint Fusion System, scheduled to commence at the beginning of the fourth quarter. This new system extends Tenon Medical’s line of implant solutions, offering a smaller, refined version of the original Catamaran fixation device. The Catamaran SE is designed to address the needs of physicians who require a more compact implant for SI joint fusion procedures.
Enhanced Design and Features
The Catamaran SE offers a notable 30% reduction in implant width compared to its predecessor, making it an ideal choice for patients with smaller SI joint anatomies or for cases where previous implants have failed and space is constrained. Additionally, the SE implant includes a manual hand drill option, catering to physicians who prefer manual drilling during the implantation process or lack access to power tools at their treatment locations.
TNON Eyeing Market Launch and Future Prospects
The alpha launch of the Catamaran SE will provide essential initial feedback from a select group of physicians, paving the way for a broader market introduction in the upcoming months. This development follows Tenon Medical’s recent announcement of positive interim outcomes from the MAINSAIL Study of the Catamaran SI Joint Fusion System.
Technical Specifications and Clinical Impact
Both the Catamaran and Catamaran SE SI Joint Fixation devices are robust, MRI-compatible titanium implants featuring two pontoons linked by an osteotome bridge. This design aims to achieve immediate fixation and stabilization of the SI joint along its longitudinal axis, supporting long-term fusion success.
Since its introduction, the Catamaran implant has been used in over 700 procedures to address primary SI joint dysfunction, sacroiliitis, and revisions of previously treated SI joints. The upcoming launch of the Catamaran SE is expected to offer physicians enhanced options for treating SI Joint disease, and Tenon Medical (NASD: TNON) anticipates a successful transition from the limited alpha launch to a full market introduction.
